How Long Tesofensine Stays in the System: What the Pharmacokinetic Literature Reports

Tesofensine Is a Small Molecule, Not a Peptide

Tesofensine, also identified in the literature by its development code NS2330, is a synthetic small-molecule monoamine reuptake inhibitor that was evaluated in neurology and metabolic research programmes rather than an amino-acid chain. Population pharmacokinetic work described tesofensine and its major metabolite in patients with Alzheimer's disease (PMID 17324246), and a randomised trial in advanced Parkinson disease with motor fluctuations administered it by mouth once daily (PMID 18474731). This distinction matters for any question about how long a compound persists: the rapid plasma clearance typical of small injected peptides is a property of peptide chemistry, not a general rule, and it does not describe an orally absorbed small molecule such as tesofensine. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Tesofensine has not been approved as a medicine by the US Food and Drug Administration, and material circulating outside of regulated pharmaceutical supply is generally labelled for research use only. The paragraphs below describe only what published investigators measured or modelled.

What the Literature Reports About Tesofensine's Half-Life

The most direct statement about the compound's elimination speed comes from drug-interaction modelling, where researchers built a semi-mechanistic population pharmacokinetic model of a long half-life substrate co-administered with itraconazole, using tesofensine as that substrate (PMID 20000889). The methodological point of that work was that a compound eliminated slowly cannot be evaluated with the short, simple interaction designs used for rapidly cleared drugs, because concentrations do not reach a new equilibrium quickly.

A separate population pharmacokinetic analysis described the disposition of tesofensine and its major metabolite in patients with Alzheimer's disease, characterising between-patient variability in a clinical trial population (PMID 17324246). Models of this type are the standard way investigators estimate clearance, volume of distribution and, from those, elimination half-life in real patients rather than in idealised single-dose volunteer studies.

Two practical consequences follow from a long half-life, and both are ordinary pharmacology rather than a finding unique to tesofensine. First, repeated daily administration of a slowly cleared compound accumulates toward steady state over a period measured in half-lives, not doses. Second, after the last administration, the decline back toward zero takes a comparable number of half-lives. Published clinical programmes that used daily oral administration over many weeks, such as the 14-week Parkinson disease trial (PMID 18474731), were therefore studying accumulated exposure rather than isolated single doses.

The Arithmetic of Half-Lives

The table below is textbook first-order elimination arithmetic. It is not a measurement taken from any tesofensine study, and it is included only to show how a half-life value translates into a washout timeline once a reader knows what that value is for a given compound.

Pharmacology texts commonly treat four to five half-lives as the point at which most of an administered amount has been eliminated. For a compound described in the modelling literature as a long half-life substrate (PMID 20000889), that multiple represents a substantially longer calendar interval than it would for a compound cleared within hours.

The Active Metabolite M1 Extends the Picture

Parent-compound half-life alone does not describe total pharmacological exposure when a metabolite is itself active. Researchers used a pharmacokinetic–pharmacodynamic modelling approach to quantify the contribution of the active metabolite M1 to the in vivo pharmacological activity of tesofensine (PMID 17982477). The population analysis in Alzheimer's disease patients likewise modelled the parent compound together with its major metabolite rather than the parent alone (PMID 17324246).

For questions about how long a compound "stays in the system", an active metabolite matters in two ways. It can be present after the parent has largely declined, and it can be the analyte that laboratory methods target. Both points are why metabolite characterisation studies exist at all.

Enterohepatic Circulation and Why Elimination Curves Are Not Simple

Some compounds are excreted into bile, delivered to the intestine and reabsorbed, producing secondary concentration peaks and an apparently prolonged terminal phase. Investigators developed and evaluated a quantitative enterohepatic circulation model using tesofensine and meloxicam as the test compounds (PMID 19705923). The fact that tesofensine data were used to build and test such a model indicates that its plasma profile was informative for recycling behaviour, and it explains why a single clean exponential decay curve may not describe measured concentrations.

Enterohepatic recycling is one of several reasons that the simple half-life arithmetic in the table above should be read as an approximation rather than a prediction of any individual's measured concentrations.

Drug Testing: What Is and Is Not Screened For

Standard workplace and clinical immunoassay panels — the familiar five-panel and ten-panel formats — are built around specific target classes such as amphetamines, cocaine metabolites, opiates, phencyclidine, cannabinoids, benzodiazepines, barbiturates and methadone. Tesofensine is not one of those targets. A routine panel does not report a tesofensine result because it never looks for one.

Whether a non-target compound produces a false signal on a class-based immunoassay depends on antibody cross-reactivity, which is established compound by compound in validation work. No paper in the verified citation set for this page reported immunoassay cross-reactivity data for tesofensine, so nothing on this page should be read as establishing that such cross-reactivity does or does not occur.

Detection of tesofensine, where it is performed at all, belongs to targeted laboratory analysis rather than screening panels. A 2026 analytical paper investigated the metabolism and elimination of tesofensine in human urine (PMID 42320973). Studies of that design identify which urinary species are present and which make the most suitable analytical targets — the groundwork required before any laboratory can test for a substance by mass spectrometry. That publication describes analytical chemistry; it does not establish a detection window for any individual, and this page does not state one.

Factors Reported or Modelled to Change Clearance

Several sources of variability appear in the tesofensine-specific literature, and others are general pharmacology that applies to orally administered small molecules broadly. The distinction is stated explicitly below.

Compound-specific findings

• Co-administered enzyme inhibitors. Researchers modelled the interaction between tesofensine, as a long half-life substrate, and itraconazole, a strong inhibitor of cytochrome P450 3A4 (PMID 20000889). Interaction work of this kind is conducted when metabolic clearance is expected to be sensitive to inhibition of a specific enzyme pathway.
• Enterohepatic recycling. The quantitative recycling model developed and evaluated with tesofensine and meloxicam data illustrates a mechanism that prolongs apparent residence time (PMID 19705923).
• Metabolite formation. The relative contribution of M1 to overall activity was quantified through pharmacokinetic–pharmacodynamic modelling (PMID 17982477).
• Between-patient variability. A population model was constructed specifically to describe variability in tesofensine and metabolite disposition across patients with Alzheimer's disease (PMID 17324246).

General pharmacology, not tesofensine-specific measurements

• Hepatic function, since metabolic clearance depends on enzyme capacity and hepatic blood flow.
• Renal function, which governs elimination of water-soluble metabolites.
• Age and body composition, which influence distribution volume and therefore terminal half-life.
• Concurrent medicines that induce or inhibit shared metabolic enzymes.
• Genetic variation in drug-metabolising enzymes.

None of the items in this second list were measured for tesofensine in the papers cited on this page; they are the standard covariates that pharmacokineticists test when building models of any orally administered small molecule.

How Exposure Was Used in Clinical Modelling: What Studies Report

Beyond concentration-time behaviour, investigators linked tesofensine exposure to clinical outcomes. A quantitative pharmacology analysis modelled efficacy from early clinical data in Alzheimer's disease in order to predict clinical outcome for tesofensine (PMID 20077053). The randomised ADVANS study evaluated tesofensine in patients with advanced Parkinson disease and motor fluctuations (PMID 18474731). These are dose-ranging and outcome studies rather than washout studies; the study designs were not built to measure how long the compound remained detectable after discontinuation, and they are cited here only for what they establish about the clinical setting in which the pharmacokinetic data were generated.

What the Evidence Does Not Establish

Three limits are worth stating plainly. First, no paper cited here reported a validated detection window in hours or days for tesofensine in urine, blood or hair; the 2026 urine paper investigated metabolism and elimination rather than publishing a population detection interval (PMID 42320973). Second, pharmacokinetic parameters derived in older adults with Alzheimer's disease (PMID 17324246) need not transfer to other populations. Third, modelled interaction effects, such as those simulated with itraconazole (PMID 20000889), are model outputs constrained by the data and assumptions used to build them.

Readers comparing this compound with injectable peptides may find the broader background page on peptide pharmacokinetics useful for context, keeping in mind that tesofensine's chemistry places it in a different kinetic category entirely.

References

• Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease (British Journal of Clinical Pharmacology, 2007)
• Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine (Drug Testing and Analysis, 2026)
• A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam (Clinical Pharmacokinetics, 2009)
• Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study (Archives of Neurology, 2008)
• Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine (The AAPS Journal, 2010)
• Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach (British Journal of Pharmacology, 2008)
• Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole (Clinical Pharmacokinetics, 2010)